Nanobiotix has been granted a patent for activable inorganic nanoparticles that can effectively treat solid tumor cancer. The method involves administering nanoparticles via intra-tumoral injection, determining the volume within the tumor, and exposing it to ionizing radiation for therapeutic effect. GlobalData’s report on Nanobiotix gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Premium Insights Nanobiotix SA - Company Profile

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Nanobiotix, Photodynamic cancer therapy drugs was a key innovation area identified from patents. Nanobiotix's grant share as of January 2024 was 43%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of solid tumor cancer using inorganic nanoparticles

Source: United States Patent and Trademark Office (USPTO). Credit: Nanobiotix SA

A recently granted patent (Publication Number: US11819548B2) discloses a method for treating solid tumor cancer by administering a composition of inorganic nanoparticles via intra-tumoral injection. The method involves determining the volume of the nanoparticles within the tumor using radiography or computed tomography and exposing the tumor to ionizing radiation. The inorganic nanoparticles must provide a specific number of electrons to the tumor, have a minimum theoretical density and effective atomic number, and occupy a specific percentage of the tumor volume.

The patent claims specify that the ionizing radiation used can include X-rays, ion beams, electron beams, gamma-rays, or a radioactive isotope. The composition of inorganic nanoparticles can be made of various materials such as oxides, metals, or mixtures thereof. The nanoparticles' size range, electron density, and the calculation of electrons provided to the tumor are also detailed in the claims. Additionally, the method allows for a combination of inorganic oxides and metals in the nanoparticles, emphasizing the importance of the nanoparticles' characteristics in effectively treating solid tumor cancer.

To know more about GlobalData’s detailed insights on Nanobiotix, buy the report here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies